A randomised controlled trial of written information
Keywords: randomised controlled trial2q, http://www.100md.com
Newsham’s effort to inform parents of children with amblyopia about occlusion therapy is laudable but incomplete.1 Ethical considerations of informed consent require full disclosure of all aspect of the proposed treatment. The following points might be considered for inclusion.2q, http://www.100md.com
Occlusion therapy has never been scientifically validated with a randomised, controlled study.2q, http://www.100md.com
The dose/response relation has never been defined. Flynn et al stated that "Success was not related to the duration of occlusion therapy, type of occlusion used . . . ."2 The variety of treatment protocols accentuate another dilemma owing to our paucity of knowledge on the dose-effect relation—a situation one finds hard to imagine for any comparably established therapy outside ophthalmology. In other words we have no understanding of the dose-effect relation of occlusion in amblyopia therapy."3
The application of "greater levels of occlusion being prescribed for more severe amblyopia"1 is compromised by the observation that success was related to " . . . the depth of visual loss before treatment . . . ."4xdd, 百拇医药
The benefits of treatment are likely to deteriorate following cessation of patching.5xdd, 百拇医药
Visual acuity improves as children become more mature, literate, and familiar with vision testing protocols.6 This is also true for amblyopic eyes. In amblyopic children between 3 and 7 years old, without treatment, visual acuity was shown to consistently improve in each older age group.7xdd, 百拇医药
Both the occluded and the amblyopic eyes improve at the same rate during treatment.8xdd, 百拇医药
Success in amblyopia treatment is usually defined as improvement by a minimum of three lines.9 Many of the successfully treated patients, by that criterion, will still not have normal vision at the end of presumably successful treatment. One quarter of treated patients with initial acuity better than 20/100 do not even achieve these limited goals.9 Therefore, the comments about achieving normal vision may raise expectations that will not be achieved.
Occlusion therapy does have potential adverse effects beyond disruption of family and social life10 and interference with education.11$?, http://www.100md.com
Despite decades of occlusion therapy the prevalence of amblyopia in the adult population is similar to that of the school age population.12 Moreover, "the prevalence of unilateral amblyopia was not found to be statistically different by age group."13 This suggests that long term benefits of conventional therapy are not demonstrated in demographic studies.$?, http://www.100md.com
Patients and their families should be provided with comprehensive information concerning proposed treatments. Physicians are obliged to make this information accurate and inclusive.$?, http://www.100md.com
References$?, http://www.100md.com
Newsham D. A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy. Br J Ophthalmol 2002;86:787–91.
Flynn JT, Schiffman J, Feuer W, et al. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc1998;96:431–50; discussion 450–3.;}, 百拇医药
Simonsz HJ, Polling JR, Voorn R, et al. Electronic monitoring of treatment compliance in patching for amblyopia. Strabismus 1999;7:113–23.;}, 百拇医药
Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus 1999;36:19–24.;}, 百拇医药
Von Noorden GK, Attiah F Alternating penalization in the prevention of amblyopia recurrence. Am J Ophthalmol 1986;102:473–5.;}, 百拇医药
Robinson BE, Oladeji MM, Bobier WR Visual acuity assessment in preschool children in Oxford County. ARVO 2000 Abst No 4955.;}, 百拇医药
The Pediatric Eye Disease Investigator Group. The clinical profile of moderate amblyopia in children younger than 7 years. Arch Ophthalmol2002;120:281–7 (Table 3 Baseline characteristics according to age at enrollment).
Dorey SE, Adams GG, Lee JP, et al. Intensive occlusion therapy for amblyopia. Br J Ophthalmol 2001;85:310–13.3p, 百拇医药
The Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002;120:268–78.3p, 百拇医药
Snowdon SL, Stewart-Brown SL. Amblyopia and disability: a qualitative study. Oxford: Health Services Research Unit University of Oxford.3p, 百拇医药
Yang LL, Lambert SR. Reappraisal of occlusion therapy for severe structural abnormalities of the optic disc and macula. J Pediatr Ophthalmol Strabismus 1995;32:37–41.3p, 百拇医药
Buch H, Vinding T, La Cour M, et al. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study Acta Ophthalmol Scand 2001;79:441–9.3p, 百拇医药
Brown SA, Weih LM, Fu CL, et al. Prevalence of amblyopia and associated refractive errors in an adult population in Victoria, Australia. Ophthalmic Epidemiol 2000;7:249–58.(P Lempert)
Newsham’s effort to inform parents of children with amblyopia about occlusion therapy is laudable but incomplete.1 Ethical considerations of informed consent require full disclosure of all aspect of the proposed treatment. The following points might be considered for inclusion.2q, http://www.100md.com
Occlusion therapy has never been scientifically validated with a randomised, controlled study.2q, http://www.100md.com
The dose/response relation has never been defined. Flynn et al stated that "Success was not related to the duration of occlusion therapy, type of occlusion used . . . ."2 The variety of treatment protocols accentuate another dilemma owing to our paucity of knowledge on the dose-effect relation—a situation one finds hard to imagine for any comparably established therapy outside ophthalmology. In other words we have no understanding of the dose-effect relation of occlusion in amblyopia therapy."3
The application of "greater levels of occlusion being prescribed for more severe amblyopia"1 is compromised by the observation that success was related to " . . . the depth of visual loss before treatment . . . ."4xdd, 百拇医药
The benefits of treatment are likely to deteriorate following cessation of patching.5xdd, 百拇医药
Visual acuity improves as children become more mature, literate, and familiar with vision testing protocols.6 This is also true for amblyopic eyes. In amblyopic children between 3 and 7 years old, without treatment, visual acuity was shown to consistently improve in each older age group.7xdd, 百拇医药
Both the occluded and the amblyopic eyes improve at the same rate during treatment.8xdd, 百拇医药
Success in amblyopia treatment is usually defined as improvement by a minimum of three lines.9 Many of the successfully treated patients, by that criterion, will still not have normal vision at the end of presumably successful treatment. One quarter of treated patients with initial acuity better than 20/100 do not even achieve these limited goals.9 Therefore, the comments about achieving normal vision may raise expectations that will not be achieved.
Occlusion therapy does have potential adverse effects beyond disruption of family and social life10 and interference with education.11$?, http://www.100md.com
Despite decades of occlusion therapy the prevalence of amblyopia in the adult population is similar to that of the school age population.12 Moreover, "the prevalence of unilateral amblyopia was not found to be statistically different by age group."13 This suggests that long term benefits of conventional therapy are not demonstrated in demographic studies.$?, http://www.100md.com
Patients and their families should be provided with comprehensive information concerning proposed treatments. Physicians are obliged to make this information accurate and inclusive.$?, http://www.100md.com
References$?, http://www.100md.com
Newsham D. A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy. Br J Ophthalmol 2002;86:787–91.
Flynn JT, Schiffman J, Feuer W, et al. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc1998;96:431–50; discussion 450–3.;}, 百拇医药
Simonsz HJ, Polling JR, Voorn R, et al. Electronic monitoring of treatment compliance in patching for amblyopia. Strabismus 1999;7:113–23.;}, 百拇医药
Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus 1999;36:19–24.;}, 百拇医药
Von Noorden GK, Attiah F Alternating penalization in the prevention of amblyopia recurrence. Am J Ophthalmol 1986;102:473–5.;}, 百拇医药
Robinson BE, Oladeji MM, Bobier WR Visual acuity assessment in preschool children in Oxford County. ARVO 2000 Abst No 4955.;}, 百拇医药
The Pediatric Eye Disease Investigator Group. The clinical profile of moderate amblyopia in children younger than 7 years. Arch Ophthalmol2002;120:281–7 (Table 3 Baseline characteristics according to age at enrollment).
Dorey SE, Adams GG, Lee JP, et al. Intensive occlusion therapy for amblyopia. Br J Ophthalmol 2001;85:310–13.3p, 百拇医药
The Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002;120:268–78.3p, 百拇医药
Snowdon SL, Stewart-Brown SL. Amblyopia and disability: a qualitative study. Oxford: Health Services Research Unit University of Oxford.3p, 百拇医药
Yang LL, Lambert SR. Reappraisal of occlusion therapy for severe structural abnormalities of the optic disc and macula. J Pediatr Ophthalmol Strabismus 1995;32:37–41.3p, 百拇医药
Buch H, Vinding T, La Cour M, et al. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study Acta Ophthalmol Scand 2001;79:441–9.3p, 百拇医药
Brown SA, Weih LM, Fu CL, et al. Prevalence of amblyopia and associated refractive errors in an adult population in Victoria, Australia. Ophthalmic Epidemiol 2000;7:249–58.(P Lempert)